Tirzepatide is a dual GIP and GLP-1 receptor agonist that showed strong metabolic effects in Phase 3 research. This guide examines its dual mechanism and research applications.
CagriSema is the combination of cagrilintide and semaglutide being studied in Phase 3 clinical trials by Novo Nordisk. It pairs
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk and studied in clinical trials both independently and in combination
Retatrutide (LY3437943) targets GLP-1, GIP, and glucagon receptors simultaneously, giving it a pharmacological profile distinct from all prior incretin research compounds.
Semaglutide is a GLP-1 receptor agonist with ~94% sequence homology to native GLP-1 and stands among the most studied metabolic research compounds of the past decade.
